Home > Boards > US OTC > Biotechs >

Insys Therapeutics Inc. (INSYQ)

INSYQ RSS Feed
Add INSYQ Price Alert      Hide Sticky   Hide Intro
Moderator: 81vette, trader59
Search This Board: 
Last Post: 10/7/2019 1:31:51 PM - Followers: 94 - Board type: Free - Posts Today: 0

INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities
Company to Facilitate Transaction Process and Sale of Substantially All Assets Through Chapter 11 of the U.S. Bankruptcy Code

Operations to Continue as Normal Including Payment of Employee Wages and Benefits and Continuing Programs for Customers; Vendors and Suppliers to Receive Full Payment for Goods and Services Provided Post-Filing
 

PHOENIX, June 10, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced today that INSYS has filed voluntary cases (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court in the District of Delaware (the “Court”) to facilitate the sale of substantially all of the Company’s assets and address the Company’s legacy legal liabilities. INSYS intends to continue operating its business in the ordinary course while it pursues these transactions through the court-supervised sale process.

Throughout the court-supervised Chapter 11 process, INSYS intends to utilize existing cash on hand and operating cash flows to support its continued operations, including payment of all employee wages and benefits without interruption and continuing programs offered to customers. The Company intends to pay vendors and suppliers in full under normal terms for goods and services provided after the filing date of June 10, 2019. To these ends, the Company has filed a number of customary motions seeking Court authorization to continue to support its business operations. INSYS expects to receive Court approval for all of these requests.

“After conducting a thorough review of available strategic alternatives, we determined that a court-supervised sale process is the best course of action to maximize the value of our assets and address our legacy legal challenges in a fair and transparent manner,” said Andrew G. Long, Chief Executive Officer of INSYS Therapeutics, Inc. “INSYS has compelling assets and a highly talented team. We believe this process will provide us with a forum to negotiate an equitable resolution with our creditors and represents the best opportunity for our people and our business.”

INSYS intends to conduct the asset sales in accordance with Section 363 of the U.S. Bankruptcy Code. The Chapter 11 process is intended to facilitate an orderly auction and sale process and maximize value for INSYS’ creditors. INSYS aims to complete the asset sales within 90 days and address creditors’ claims as efficiently and expeditiously as possible.

Court documents and additional information can be found at a website administered by INSYS’ claims agent, Epiq, at https://dm.epiq11.com/Insys or by calling the Company’s Restructuring Hotline, toll-free in the U.S., at (855) 424-7683. For calls originating outside of the U.S., please dial +1 (503) 520-4461.

Weil, Gotshal & Manges LLP is serving as legal counsel to INSYS, Lazard Frères & Co. LLC is serving as investment banker, and FTI Consulting, Inc. is serving as financial advisor.

About INSYS

INSYS Therapeutics is a specialty pharmaceutical company using proprietary technology and capabilities to develop and commercialize innovative pharmaceutical products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “intend” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words.  All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects, believes, targets or anticipates will or may occur in the future are forward-looking statements. The Company’s actual results may differ materially from those anticipated in these forward-looking statements as a result of certain risks and other factors, which could include the following: risks and uncertainties relating to the Chapter 11 Cases, including but not limited to, the Company’s ability to obtain Court approval with respect to motions in the Chapter 11 Cases, the effects of the Chapter 11 Cases on the Company and on the interests of various constituents, Court rulings in the Chapter 11 Cases and the outcome of the Chapter 11 Cases in general, the length of time the Company will operate under the Chapter 11 Cases, risks associated with third-party motions in the Chapter 11 Cases, the potential adverse effects of the Chapter 11 Cases on the Company’s liquidity or results of operations and increased legal and other professional costs necessary to execute the Company’s reorganization; the effects of disruption from the Chapter 11 Cases making it more difficult to maintain business and operational relationships, to retain key executives and to maintain various licenses and approvals necessary for the Company to conduct its business; uncertainty associated with the Company’s ability to complete the sale of its assets as contemplated by the Chapter 11 Cases; trading price and volatility of the Company’s common stock and the ability of the Company to remain listed on Nasdaq as well as other risk factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. The Company therefore cautions readers against relying on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on the Company’s behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and, except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Investor Relations & Corporate Communications
Jackie Marcus or Chris Hodges
Alpha IR Group
312-445-2870
INSY@alpha-ir.com

or

Michael Freitag / Matthew Gross / Andrew Squire
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

https://marketwirenews.com/news-releases/insys-therapeutics-initiates-court-supervised-process-to-facilitate-asset-sales-and-address-legacy-liabilities-8328858.html



SEC Form 8-K     https://www.otcmarkets.com/filing/html?id=13485277&guid=jwnyUHVJ3HALXyh

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on June 10, 2019, Insys Therapeutics, Inc. (the “Company”) and its subsidiaries filed voluntary petitions (the “Chapter 11 Cases”) for relief under chapter 11 of title 11of the United States Code in the United States Bankruptcy Court for the District of Delaware.

On June 10, 2019, the Company received a letter form the listing qualifications department staff of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq has determined that the Company’s securities will be delisted from Nasdaq. Accordingly, unless the Company requests an appeal of this determination, trading of the Company’s securities will be suspended at the opening of business on June 19, 2019 and a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on Nasdaq.

The Company does not intend to appeal the determination and, therefore, it is expected that the Company’s securities will be delisted. The Company expects the trading of its securities will be eligible to be quoted on the over-the-counter market on June 19, 2019, but no assurance can be made that trading in the Company’s securities on the over-the-counter market will commence or be maintained. The transition does not affect the Company’s operations and does not change reporting requirement under SEC rules.

The Company cautions that trading in the Company’s securities during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders of the Company’s securities in the Chapter 11 Cases. It is unlikely that holders of the Company’s common stock will receive any recovery on account of such securities.

 

INSYQ
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#1622  Sticky Note News: $INSY INSY Stock Jumps 240%: Gets "First whytestocks 06/12/19 01:20:40 PM
#1699   events on mon,could see run today 81vette 09/27/19 09:25:14 AM
#1698   Item 1.01Entry into a Material Definitive Agreement. 81vette 09/26/19 12:30:40 PM
#1697   royalty payments 45% of net sales are coming,INSYQ 81vette 09/26/19 12:26:37 PM
#1696   8k just released,drug that caused their suit being 81vette 09/26/19 12:07:19 PM
#1695   all board of directors and managers are new 81vette 09/26/19 11:55:07 AM
#1694   $300,000 traded yesterday,$90,000 so far today, defunct Qs 81vette 09/26/19 11:20:02 AM
#1693   6 day run,yesterdays candle on the bolie,today just 81vette 09/26/19 11:14:39 AM
#1692   pps was $45 in 2016,orphan drug approval news coming 81vette 09/26/19 11:10:05 AM
#1691   90k demand,next leg coming,chase on 81vette 09/26/19 10:47:30 AM
#1690   first ever opioid bankruptcy suit,emerged ok(wasn't completely destroyed,lol)ot 81vette 09/26/19 10:45:07 AM
#1689   big$$$ was in the court rooms,attorneys,judges,ect.all thinking I 81vette 09/26/19 10:38:59 AM
#1688   bankruptcy was to protect them from the lawsuit,its 81vette 09/26/19 10:35:32 AM
#1687   sweet pull back from overbought,needed that for healthy continue 81vette 09/26/19 10:20:45 AM
#1686   Yep, and especially when a bankrupt company tells trader59 09/26/19 07:48:37 AM
#1685   The Company cautions that trading in the Company’s davidsson10 09/26/19 06:45:53 AM
#1684   Im Up Over 200% On This "DEAD" Company!!! mulder35 09/25/19 11:13:34 AM
#1683   LOL. Who is? This company is dead. trader59 09/19/19 05:23:10 PM
#1682   ANYONE LEFT??? HOOOOOOLD YOUR SHARES!!!! THEY'VE RUN OUT!!! mulder35 09/19/19 09:42:20 AM
#1681   .09 Cents??!!! Guess its only ME on this mulder35 09/10/19 01:26:36 PM
#1680   Mun5 I cant tell IF its Approved? One mulder35 08/20/19 12:12:09 PM
#1679   INSYQ: FDA approval posted on FDA website. NOT mun5 08/20/19 10:34:07 AM
#1678   With $175M of assets and $262M of debt, trader59 08/19/19 04:17:33 PM
#1677   INSYQ: FDA approves Orphan Drug Status for epilepsy. mun5 08/19/19 03:53:47 PM
#1676   Brnovich announced his office filed a consumer law Koog 07/18/19 08:46:26 PM
#1675   News is strong an the recovery is in WallStreetMyWay 07/17/19 12:16:55 PM
#1674   Bought some on the changes an recovery of WallStreetMyWay 07/17/19 12:15:21 PM
#1673   Means most likey the postioing to contuines added WallStreetMyWay 07/17/19 10:14:25 AM
#1672   Dead stock here. The company said they're trader59 07/15/19 08:47:36 PM
#1671   Nice movement today .. let’s hope it continues GoldiS 07/15/19 06:20:41 PM
#1670   Come check out my last post when u Tha Part Time Er 07/09/19 02:18:00 PM
#1668   INSYQ $$$ SHOULD EXPLODE FRIDAY AND NEXT WEEK...HUGE halbroke1 07/04/19 02:08:57 PM
#1667   The good news is that Insys will never Koog 07/03/19 03:12:14 PM
#1666   The tech/products they have will be bought, there's trader59 07/03/19 11:52:45 AM
#1665   $INSYQ: I know... looks like an $AKAOQ situation makinezmoney 07/03/19 11:50:38 AM
#1664   It's too bad this company has massive debt trader59 07/03/19 11:49:21 AM
#1663   $INSYQ: FDA APPROVAL for Naloxone Nasal Spray makinezmoney 07/03/19 08:44:00 AM
#1662   resistance at 0.30 tamby1 06/24/19 10:34:02 AM
#1661   FTDCQ Like FTDCQ better 1 billion in assets and jdp2000 06/24/19 09:10:58 AM
#1660   This will be a liquidation of their assets, trader59 06/19/19 05:00:08 PM
#1659   Stocks Do Funny Things in OTC Land… HOLD. mulder35 06/19/19 01:15:43 PM
#1658   I don't have any losses. Just flipped for 420man 06/19/19 12:14:29 PM
#1657   $INSY $INSYQ Cut your losses and check SpotOnTrade 06/19/19 12:11:38 PM
#1656   Out @ .30 for now. 420man 06/19/19 09:47:52 AM
#1655   In @ .22 420man 06/19/19 09:42:01 AM
#1654   Oh..I don't own any, but let's say if 420man 06/18/19 07:28:40 PM
#1653   haha, yeh, $672.00 is quite the boo boo. Renee 06/18/19 07:24:46 PM
#1652   If it opens according to the chart on 420man 06/18/19 07:21:55 PM
#1651   INSY changed to INSYQ. Delisted from the Nasdaq Renee 06/18/19 06:48:14 PM
#1650   https://en.m.wikipedia.org/wiki/Market_manipulation 420man 06/18/19 06:09:16 PM
#1649   INSY delisted from Nasdaq ......https://otce.finra.org/otce/dailyList Will open on 420man 06/18/19 05:48:18 PM
PostSubject